Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 5/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 8/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408314 | 0.83 | — | — | |
| SCHEMBL25407585 | 0.78 | TLR9 (0.34) | — | |
| SCHEMBL25408541 | 0.75 | GPR119 (0.40) | RETSUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL25408196 | 0.73 | PIM1 (0.32) | — | |
| SCHEMBL25235906 | 0.70 | TLR9 (0.38) | — | |
| SCHEMBL26309282 | 0.69 | CKS1B (0.47) | RETSUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL25407485 | 0.68 | TLR9 (0.38) | SUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL30338062 | 0.68 | TLR9 (0.38) | SUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL25276459 | 0.68 | TLR9 (0.35) | RAF1 | |
| SCHEMBL25280724 | 0.66 | RET (0.44) | RETSUV39H2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-115835911-A | Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, CNKSR1, UACA | RAF1 157/4885RET 464/4885SUV39H2 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.